ClinicalTrials.gg
CompletedNCT00367770Updated Sep 22, 2016Results posted

BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology

A Phase 4 interventional study of Tracleer® in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 17 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2016-09-22.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.

Enrollment
9th of 18
37 · median 37
Started
2004
with 1 other
Phase 4
5 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
10 of 18
Actelion

Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one is the 9th largest by enrollment, is one of 2 that started in 2004, is one of 5 in phase 4, and was the 7th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

About bosentan

Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing bosentan in Pulmonary Arterial Hypertension as a file.
02

Study summary

This 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5 study (PAH related to Eisenmenger physiology). Treatment duration is 6 months.

Read the detailed description

This is a multicenter, open-label, single -arm study with bosentan, initial dose of 62.5 mg b.i.d., with a target dose of 125 mg b.i.d. All patients will be assessed for eligibility during the baseline visit (same as Week 16, end of study BREATHE-5 visit), and will have the option to enter into the open-label extension study at a starting dose of 62.5 mg b.i.d., for safety reasons. Visit 2 is required as a safety visit to assess oxygen saturation (SpO2) after 1 week of bosentan treatment. Patients will return for Visit 4 after 4 weeks of treatment, and the dose will be up-titrated to 125 mg b.i.d. or maintained at 62.5 mg b.i.d. at the judgement of the investigator. Data will be collected for a total of 24 weeks or until the sponsor decides to stop the study. If the results from Study AC-052-403 or AC-052-405 demonstrate significant safety issues, this extension study may be terminated at the sponsor's request.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • bosentan
  • PAH related to Eisenmenger physiology
  • Tracleer
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients stable with PAH upon completion of the BREATHE-5 randomized, double-blind, placebo- controlled 16-week study.
  2. For female patients, only non-pregnant women who are surgically sterile, or have documented infertility (over 50 years of age and amenorrheic for at least 1 year), or those of using one of the following methods of : Barrier-type devices (e.g., condom, diaphragm) used ONLY in combination with a spermicide. A double-barrier method is recommended; intrauterine devices (IUDs); oral or implanted contraceptives, if used in combination with a barrier method.
  3. Patients providing written .

Exclusion criteria

Exclusion Criteria:

  1. Patients who withdrew prematurely from BREATHE-5, AC-052-405.
  2. Patients who are pregnant or nursing.
  3. Patients who are receiving epoprostenol or prostacyclin analogues, or are expected to receive any of these drugs during the study.
  4. Patients with and/or ALT values greater than 3 times the .
  5. Patients with or hematocrit that is more than 30% below the normal range (patients with secondary polycythemia are permitted in the study).
  6. Patients with systolic blood pressure \< 85 mm Hg.
  7. Patients taking phosphodiesterase inhibitors, other endothelin receptor antagonists or are receiving another product.
  8. Patients active on organ transplant list.
  9. Patients who are receiving or expected to receive glyburide, cyclosporin A or tacrolimus.
  10. Patients not able to comply with the protocol or adhere to therapy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Tracleer

    The starting dose for all patients will be 62.5 mg b.i.d. At the Week 4 visit, patients who were started on 62.5 mg b.i.d. will be uptitrated to 125 mg b.i.d. if the 62.5 mg b.i.d. dose was well-tolerated.

    Drug: Tracleer®

Interventions

  • Patients will receive up to 125 mg b.i.d. of Tracleer.

06

What researchers measure

Primary outcomes

  1. Change in 6-minute Walk Distance

    Time frame: from baseline to week 24

  2. Change in Borg Dyspnea Index

    Borg scale a numerical scale for assessing dyspnea, from 0 representing no dyspnea to 10 as maximal dyspnea.

    Time frame: from baseline to week 24

  3. Number of Participants With a Change in WHO Functional Class

    Number of participants with a change in WHO functional class from baseline to week 24. A change from a higher to a lower functional class (i.e. III to II, III to I or II to I) is considered as an improvement.

    Time frame: from baseline to week 24

07

Results

Posted Aug 15, 2016

Participant flow

Eight centers in six countries: Germany (1), Italy (2), the Netherlands (1), Spain (1), U.K. (2), U.S.A. (1) Patients with stable PAH upon completion of the BREATHE-5 randomized, double-blind, placebocontrolled 16-week study were given option to enter into the open-label extension study.

Participant flow — Overall Study
MilestoneTracleer
Started37
Completed35
Not completed2
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange in 6-minute Walk Distance
Time frame:
from baseline to week 24
Reported as:
Mean · m
Change in 6-minute Walk Distance
mOverall Study Arm
Change in 6-minute Walk Distance13.5 ± 57.2
PrimaryChange in Borg Dyspnea Index

Borg scale a numerical scale for assessing dyspnea, from 0 representing no dyspnea to 10 as maximal dyspnea.

Time frame:
from baseline to week 24
Reported as:
Mean · units on a scale
Change in Borg Dyspnea Index
units on a scaleOverall Study Arm
Change in Borg Dyspnea Index0.1 ± 1.4
PrimaryNumber of Participants With a Change in WHO Functional Class

Number of participants with a change in WHO functional class from baseline to week 24. A change from a higher to a lower functional class (i.e. III to II, III to I or II to I) is considered as an improvement.

Time frame:
from baseline to week 24
Reported as:
Number · participants
Number of Participants With a Change in WHO Functional Class
participantsOverall Study Arm
Number of Participants With a Change in WHO Functional Class13

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tracleer—7/37 (18.9%)25/37 (67.6%)
Most frequent serious events
Most frequent serious events
EventTracleer
ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions2/37
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/37
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations1/37
GASTROENTERITIS VIRALInfections and infestations1/37
LETHARGYNervous system disorders1/37
NAUSEAGastrointestinal disorders1/37
PALPITATIONSCardiac disorders1/37
pregnancyPregnancy, puerperium and perinatal conditions1/37
sudden deathGeneral disorders1/37
rectal hemorrhageGastrointestinal disorders1/37
Most frequent other events
Showing 10 of 15
Most frequent other events
EventTracleer
OEDEMA PERIPHERALGeneral disorders7/37
NASOPHARYNGITISInfections and infestations5/37
CHEST PAINGeneral disorders4/37
DIARRHOEAGastrointestinal disorders3/37
FATIGUEGeneral disorders2/37
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations2/37
VIRAL INFECTIONInfections and infestations2/37
NASAL CONGESTIONRespiratory, thoracic and mediastinal disorders2/37
PALPITATIONSCardiac disorders2/37
DIZZINESSNervous system disorders2/37

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Overall Study Arm
Mean39.8 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study Arm
Female25
Male12
08

Study locations

17 sites
  • BACH Pulmonary Hypertension Service
    Boston, Massachusetts 02115, United States
  • Texas Children's Hospital
    Houston, Texas 77030-2303, United States
  • Royal Prince Alfred Hospital - Central Clinical School
    Camperdown, NSW 2050, Australia
  • The Royal Melbourne Hospital
    Victoria, 3050, Australia
  • Universitatsklinikum fur Innere Medizin II
    Wien, AT-1090, Austria
  • UZ Gasthuisberg
    Leuven, BE-3000, Belgium
  • The Peter Lougheed Centre
    Calgary, Alberta T1Y 6J4, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Hospital Necker-Enfants Malades
    Paris, 75007, France
  • Herzzentrum NRW
    Bad Oeynhausen, D-32545, Germany
  • Deutsches Herzzentrum Munchen
    Munchen, D-80636, Germany
  • University of Bologna
    Bologna, 40138, Italy
  • San Matteo Hospital
    Pavia, 27100, Italy
  • Academisch Ziekenhuis Groningen
    Groningen, 9713 GZ, Netherlands
  • Unidad Medico Quirurgica de Cardiologia - Edificio General
    Madrid, 28046, Spain
  • Scottish Vascular Unit - Western Infirmary
    Glasgow, G11 6NT, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 10 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2006
First posted
Aug 23, 2006
Start
Jan 2004
Primary completionActual
Dec 2005
CompletionActual
Dec 2005
Results first posted
Aug 15, 2016
Last update
Sep 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00367770
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Aug 23, 2006
Start date
Jan 2004
Primary completion
Dec 2005
Completion
Dec 2005
Results posted
Aug 15, 2016
Last update
Sep 22, 2016

Study contacts

Michael Landzberg, MD
study chair · BACH Pulmonary Hypertension Service, Boston, U.S.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion